Stock Taper
PEPG
PEPGEN INC.
NASDAQ
$3.08
▲ UP 0.33% (0.01)

KEY STATISTICS

Market Cap$213.04 M
52w High$7.80
52w Low$1.17
Dividend Yield
Frequency
P/E-2.35
Volume484.87K
Shares Out.69.17M

COMPANY

LEADERSHIP

James G. McArthur
CHIEF EXECUTIVE
James G. McArthur

COMPENSATION 2026

Salary$619,000
Stock Awards$170,620
Incentive Plan Pay$0
All Other Comp.$10,500
Total$3,316,783

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 6, 2022
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
57

PRICE TARGET

Target High$4.00
Target Low$4.00
Target Median$4.00
Target Consensus$4.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.
NOV
11
WED

PRICE

$3.08 ▲ UP 0.33% (+$0.01)
$3.00$3.04$3.08$3.129:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.08

About PepGen Inc.

https://www.pepgen.com ↗

PepGen Inc. is a Cambridge-based biotech developing oligonucleotide therapeutics, including PGN-EDO51 for Duchenne muscular dystrophy and other candidates for neuromuscular and neurologic diseases.

INDUSTRY

Biotechnology

A PRODUCT PEPGEN INC. IS KNOWN FOR

PGN-EDODM1
PGN-EDODM1

PGN-EDODM1 is an investigational peptide-conjugated oligonucleotide therapeutic in clinical trials for Myotonic Dystrophy Type 1, now PepGen’s lead candidate after discontinuing its Duchenne muscular dystrophy program.

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 34.0K shares
2026-06-18
DIRECTOR
Wyman Lisa
Purchase · 34.0K shares
2026-06-18
DIRECTOR
Resnick Joshua
Purchase · 34.0K shares
2026-06-18
DIRECTOR
Mayer Howard
Purchase · 34.0K shares
2026-06-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
FATE$2.43COMPARE
ALEC$2.34COMPARE
CRBP$10.91COMPARE
NKTX$2.76COMPARE
MOLN$4.50COMPARE
CRDF$0.94COMPARE
ELTX$2.84COMPARE